Free Trial

CVS Health (CVS) Stock Forecast & Price Target

CVS Health logo
$77.89 +1.15 (+1.50%)
Closing price 10/10/2025 03:59 PM Eastern
Extended Trading
$77.85 -0.04 (-0.05%)
As of 10/10/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
4
Buy
21

Based on 25 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 25 analysts, 4 have given a hold rating, 19 have given a buy rating, and 2 have given a strong buy rating for CVS.

Consensus Price Target

$79.80
2.45% Upside
According to the 25 analysts' twelve-month price targets for CVS Health, the average price target is $79.80. The highest price target for CVS is $103.00, while the lowest price target for CVS is $65.00. The average price target represents a forecasted upside of 2.45% from the current price of $77.89.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CVS Analyst Ratings Over Time

TypeCurrent Forecast
10/12/24 to 10/12/25
1 Month Ago
9/12/24 to 9/12/25
3 Months Ago
7/14/24 to 7/14/25
1 Year Ago
10/13/23 to 10/12/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
19 Buy rating(s)
19 Buy rating(s)
17 Buy rating(s)
13 Buy rating(s)
Hold
4 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$79.80$77.89$75.38$75.26
Forecasted Upside2.45% Upside3.86% Upside17.11% Upside12.96% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CVS Health Stock vs. The Competition

TypeCVS HealthMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.33
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside2.45% Upside1,022.61% Upside177.76% Upside
News Sentiment Rating
Positive News

See Recent CVS News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/9/2025Mizuho
3 of 5 stars
Ann Hynes
Ann Hynes
3 of 5 stars
Boost TargetOutperform$76.00 ➝ $88.00+14.37%
10/7/2025Wells Fargo & Company
3 of 5 stars
Stephen Baxter
Stephen Baxter
4 of 5 stars
Boost TargetOverweight$84.00 ➝ $103.00+34.01%
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C-)
9/22/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$80.00 ➝ $85.00+14.17%
9/8/2025Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeStrong-BuyHold
9/5/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetMarket Perform$72.00 ➝ $77.00+4.30%
9/4/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$80.00 ➝ $87.00+18.63%
8/26/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$78.00+9.52%
8/18/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$67.00 ➝ $79.00+15.23%
8/14/2025Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldStrong-Buy
8/14/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralOutperform$71.00 ➝ $82.00+24.41%
8/4/2025Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
8/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$80.00 ➝ $82.00+31.12%
7/16/2025Bernstein Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetMarket Perform$78.00 ➝ $72.00+12.86%
6/30/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$74.00 ➝ $80.00+16.43%
5/12/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$82.00 ➝ $84.00+32.07%
5/5/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$74.00 ➝ $81.00+19.23%
3/21/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$72.00 ➝ $74.00+7.70%
2/18/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Set Target$77.00+16.93%
2/18/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$80.00 ➝ $81.00+23.71%
2/13/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$55.00 ➝ $75.00+18.61%
2/12/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
1/30/2025Edward Jones
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy
1/27/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$60.00 ➝ $65.00+15.59%
12/3/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy$66.00 ➝ $66.00+11.73%
11/25/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$73.00 ➝ $80.00+33.11%
5/2/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$95.00 ➝ $77.00+41.73%
5/2/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$85.00 ➝ $74.00+36.08%
12/22/2023HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageBuy$94.00+19.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:33 AM ET.


Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 11, 2025. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CVS Health Co.:

  • CVS Health Co. recently reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a solid revenue growth of over 8% compared to the same quarter last year, reflecting its ability to expand its market presence.
  • CVS Health Co. has a current stock price around $76.78, which is near its 1-year high, suggesting positive market sentiment and potential for further appreciation.
  • The firm has announced a quarterly dividend of $0.665 per share, providing a reliable income stream for investors, with a dividend yield of approximately 3.5%.
  • With a return on equity of over 10%, CVS Health Co. demonstrates effective management and profitability, which can be attractive to investors seeking stable returns.

CVS Health
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CVS Health Co. for these reasons:

  • The company's net margin is relatively low at 1.17%, which may indicate challenges in maintaining profitability amidst rising operational costs.
  • CVS Health Co. has a debt-to-equity ratio of 0.74, suggesting a moderate level of debt that could pose risks if interest rates rise or if the company faces financial difficulties.
  • Insider selling activity has been noted, with a director recently selling a significant number of shares, which could signal a lack of confidence in the company's future performance.
  • Despite recent growth, analysts project earnings per share for the current fiscal year to be lower than the previous year, indicating potential challenges ahead.
  • The stock has shown volatility, with a 1-year low of $43.56, which may concern risk-averse investors looking for stability.

CVS Forecast - Frequently Asked Questions

According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $79.80, with a high forecast of $103.00 and a low forecast of $65.00.

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last year. There are currently 4 hold ratings, 19 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CVS shares.

According to analysts, CVS Health's stock has a predicted upside of 2.45% based on their 12-month stock forecasts.

Over the previous 90 days, CVS Health's stock had 3 upgrades and 1 downgrade by analysts.

Analysts like CVS Health more than other "medical" companies. The consensus rating for CVS Health is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how CVS compares to other companies.


This page (NYSE:CVS) was last updated on 10/12/2025 by MarketBeat.com Staff
From Our Partners